In conclusion, our multi-platform data suggest that UBE2S and HIF1α may represent critical biomarkers in ESCC. Their consistent overexpression and association with adverse outcomes support their potential for improving risk stratification and lay the groundwork for exploring them as future therapeutic targets.
Ma et al. (Wed,) studied this question.